Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Brownstone, Nicholas; Thibodeaux, Quinn; Reddy, Vidhatha; Myers, Bridget; Chan, Si-Wa; Bhutani, Tina; Liao, Wilson

doi:10.1007/s13555-020-00394-8

Cited by 13 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, case series (10,11) indicated that the biologic seemed to be protective against the onset and the severity of COVID-19. Further, 3 case reports (12)(13)(14) demonstrated the mild form of COVID-19 in psoriatic patients. However, the strengths (novelty, high applicability in the pandemic of COVID-19, and in depth analysis) and limitations of such studies (the absence of generalization, lack of cause-effect relationship, and publication bias) should be considered while their results are interpreted.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 and psoriasis: biologic treatment and challenges

Ebrahimi

Sayad

Rahimi

2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Background: There is concern about susceptibility of psoriatic patients on biologics to coronavirus disease 2019 (COVID-19) and its clinical course. Purpose: The aims of present review were to determine whether the biologic treatment of psoriasis increases the risk of SARS-CoV-2 infection and if biologics affect the clinical course of COVID-19 in these patients. Methods: We searched database of MEDLINE (PubMed) for key term of psoriasis biologic and COVID-19 until June 9, 2020 and all published 14 papers and an experience from Iran (10509 cases) related to the psoriatic patients on biologics and COVID-19 along with relevant papers were summarized. In spite of limitation in some reports, due to some of strengths that will be discussed, all papers were included in this review. Results: According to 8769 medical reports around 0.3% of psoriatic patients had COVID-19 and the rate of hospitalization was 0.1%. No death due to COVID-19 was reported among 10509 patients. Reports indicated psoriatic patients on biologics were not more susceptible to COVID-19 and the severe clinical course of disease. Conclusion: While there is not definitive controlled trial data, the available evidence suggests that patients with psoriasis without COVID-19 can continue the biologic therapy for psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 and psoriasis: biologic treatment and challenges

Ebrahimi

Sayad

Rahimi

2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

show abstract

“…Withholding biologics and transitioning to safer alternatives may be considered to avoid complications, and initiation of biologic therapy is not recommended in active SARS-CoV-2 infection [ 195 – 198 ]. Moreover, patients should be carefully assessed before a biologic is discontinued because of the risk of diminished treatment response with re-initiation and the development of antibodies, erythroderma, or disease flare [ 196 , 199 ]. Our treatment algorithm focuses on patients who are negative for COVID-19 and are not at high-risk for SARS-CoV-2 infection.…”

Section: Comorbid Conditions and Special Populationsmentioning

confidence: 99%

“…Two cases have been reported of patients with psoriasis receiving biologics who achieved full recovery from COVID-19 with outpatient supportive therapy [ 199 ]. One patient started ustekinumab 3 years prior to COVID-19 diagnosis.…”

Section: Comorbid Conditions and Special Populationsmentioning

confidence: 99%

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review

et al. 2021

View full text Add to dashboard Cite

The emergence of data from clinical trials of biologics, the approval of new biologics, and our improved understanding of psoriasis pathogenesis have increased the therapeutic possibilities for the treatment of moderate-to-severe psoriasis. Biologics currently approved for the treatment of psoriasis include tumor necrosis factor inhibitors, interleukin (IL)-17 inhibitors, ustekinumab (an IL-12/23 inhibitor), and IL-23 inhibitors. Data from clinical trials and studies of the safety and efficacy of biologics provide essential information for the personalization of patient care. We discuss the benefits and disadvantages of biologics as a first-line treatment choice, update treatment recommendations according to current evidence, and propose psoriasis treatment algorithms. Our discussion includes the following comorbid conditions: psoriatic arthritis, multiple sclerosis, congestive heart failure, inflammatory bowel disease, hepatitis B, nonmelanoma skin cancer, lymphoma, and latent tuberculosis. We make evidence-based treatment recommendations for special populations, including pediatric patients, patients with coronavirus 2019 (COVID-19), and pregnant and breastfeeding patients with psoriasis. Ultimately, individualized recommendations that consider patient preferences, disease severity, comorbid conditions, and additional risk factors should be offered to patients and updated as new trial data emerges.

show abstract

“…Biologics for the treatment of psoriasis inhibit TNF, IL-12/23, IL-23, and IL-17 ( Table 2 ). There are many case reports of psoriasis patients who presented with mild COVID-19 infections during biologic therapy and had favorable outcomes [ 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 ]; however, biologic therapy did not suppress the progression of COVID-19, which resulted in acute respiratory distress syndrome (ARDS) [ 39 ]. In COVID-19 patients, higher levels of TNF have been observed [ 40 ].…”

Section: Biologics For Psoriasismentioning

confidence: 99%

Biologics for Psoriasis during the COVID-19 Pandemic

Komine

Ohtsuki

2021

JCM

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.

show abstract

Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Cited by 13 publications

References 7 publications

COVID-19 and psoriasis: biologic treatment and challenges

COVID-19 and psoriasis: biologic treatment and challenges

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review

Biologics for Psoriasis during the COVID-19 Pandemic

Contact Info

Product

Resources

About